Results 211 to 220 of about 71,002 (280)

Homoisoflavonoids—From Natural Specificity and Biosynthesis to Precision Health‐Promoting Mechanisms

Food Frontiers, Volume 7, Issue 3, May 2026.
Homoisoflavonoids are rare flavonoids with a unique bi‐aromatic oxygen‐heterocyclic structure. This review synthesizes their structure–activity relationships in anti‐inflammatory, hypoglycemic, and anticancer contexts. By highlighting their specific natural distribution and outlining biosynthetic pathways, it provides a conceptual framework and ...
Jing Zhang, Han Chen, Jinping Si, Zhigang Han, Xinfeng Zhang   +4 more
wiley   +1 more source

Role of poly-ADP-ribose polymerase inhibitors after brain progression in platinum-sensitive ovarian cancer: a case report and review of the literature. [PDF]

Front Oncol
Lendinez-Sanchez G, Diaz-Redondo T, Iglesias-Campos M, Garrido-Almazán L, Alba-Conejo E, Rueda-Dominguez A, Sanchez-Muñoz A.   +6 more
europepmc   +1 more source

Limitations of Subgroup Safety Analyses for Drug–Drug Interaction Evaluation: Insights from the Talazoparib P‐gp Inhibitor Case

The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract Impact of concomitant medications (conmeds) on the safety of the investigational agent is often evaluated using subgroup analyses for safety events in patients who received the conmed versus those who did not. Here, we highlight the potential biases and inconclusive results that can arise from such analyses, using talazoparib and P ...
Diane Wang, Charvi Nanavati, Derek Z. Yang, Liza DeAnnuntis, Mohamed Elmeliegy   +4 more
wiley   +1 more source

The promising role of poly(ADP-ribose) polymerase inhibitors in prostate cancer

Asian Journal of Andrology, 2016
Jeanny B Aragon-Ching
doaj   +1 more source

Synergistic Cytotoxicity of Histone Deacetylase and Poly-ADP Ribose Polymerase Inhibitors and Decitabine in Breast and Ovarian Cancer Cells: Implications for Novel Therapeutic Combinations. [PDF]

Int J Mol Sci
Valdez BC, Tsimberidou AM, Yuan B, Baysal MA, Chakraborty A, Andersen CR, Andersson BS.   +6 more
europepmc   +1 more source

Population Pharmacokinetic Modeling of Niraparib to Assess Different Absorption Models

The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract Niraparib is a poly(ADP‐ribose) polymerase inhibitor approved for maintenance treatment of advanced ovarian cancer. Using data from a previous niraparib population pharmacokinetic (PK) model with data from four studies, this model added phase 1 pharmacokinetic data from two studies.
Anna Gaffney, Yoko Franchetti, Mathieu Desrosiers, Mirjam N. Trame, Roxanne C. Jewell   +4 more
wiley   +1 more source

Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in pancreatic cancer cells: Implications for novel therapy. [PDF]

Oncotarget
Valdez BC, Tsimberidou AM, Yuan B, Nieto Y, Baysal MA, Chakraborty A, Andersen CR, Andersson BS.   +7 more
europepmc   +1 more source

Poly(ADP-ribose) polymerases as modulators of mitochondrial activity [PDF]

, 2019
Bai, Péter, Fodor, Tamás, Liaudet, Lucas, Nagy, Lilla Nikoletta, Pacher, Pál   +4 more
core   +1 more source

DNA Copy Number Profiling in Extracellular Vesicles as Clinical Biomarkers of High‐Grade Serous Ovarian Carcinoma

Journal of Extracellular Vesicles, Volume 15, Issue 5, May 2026.
ABSTRACT Extracellular vesicles (EVs), including exosomes, circulate in body fluids and carry pathological genomic information. High‐grade serous ovarian carcinoma (HGSOC) is the most common subtype of ovarian cancer, characterized predominantly by copy number variations (CNVs).
Ryosuke Uekusa, Akira Yokoi, Mayu Ukai, Kosuke Yoshida, Kunanon Chattrairat, Takao Yasui, Yasuhide Inokuma, Masami Kitagawa, Eri Asano‐Inami, Masato Yoshihara, Satoshi Tamauchi, Nobuhisa Yoshikawa, Kaoru Niimi, Juntaro Matsuzaki, Takahiro Ochiya, Anil K. Sood, Yusuke Yamamoto, Hiroaki Kajiyama   +17 more
wiley   +1 more source

Treatment Response and Outcomes of Prostate Cancer Patients Carrying the Germline MMS22L F722fs Mutation

The Prostate, Volume 86, Issue 6, Page 727-731, May 2026.
ABSTRACT Background Methyl Methanesulfonate‐Sensitivity Protein 22‐Like (MMS22L) plays a key role in homology‐directed DNA repair, and experimental models have shown that its loss confers sensitivity to Poly (ADP‐ribose) polymerase inhibitors (PARPi).
Mayuko Kanayama, Violet A. Daniels, Marta Gielzak, Alex Brame, Misop Han, Li Jia, Jianfeng Xu, Tamara L. Lotan, Mario A. Eisenberger, Catherine H. Marshall, Patrick C. Walsh, William B. Isaacs, Jun Luo   +12 more
wiley   +1 more source